
|Videos|May 2, 2022
Accelerating clinical studies in retina: What Ora Clinical is doing to help
Author(s)David Hutton, Emily Kaiser Maharjan
Dr. David Bingaman of Ora Clinical discusses today’s need to accelerate clinical studies and increase investments in retina and challenging disease states.
Advertisement
David Hutton, executive editor of Ophthalmology Times®, sits down with David Bingaman, DVM, PhD, Chief Development Officer of Ora Clinical to discuss the need to accelerate clinical trials and increase investments in retina research. Dr. Bingaman also discusses Ora Clinical’s presence at ARVO 2022.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Ophthalmology Times - Clinical Insights for Eye Specialists
1
Bayer acquires Perfuse Therapeutics, partners with Iambic to expand ophthalmology and AI capabilities
2
Memento Medicines launches with $93 million Series A to advance Tie2-activating bispecific for retinal disease
3
iOpeners with Nicole Bajic, MD: Nikolina Budimlija, MD, on building a multidisciplinary dry eye clinic in Ireland
4
Obstructive sleep apnea and glaucoma: What a 12.5-million-patient data set reveals
5


























